Legend Biotech (NASDAQ:LEGN) Given Outperform Rating at Royal Bank of Canada
Legend Biotech (NASDAQ:LEGN – Get Free Report)‘s stock had its “outperform” rating reiterated by analysts at Royal Bank of Canada in a report released on Friday, Benzinga reports. They currently have a $86.00 target price on the stock. Royal Bank of Canada’s target price would indicate a potential upside of 74.55% from the stock’s current […]
29 Sep 03:39 · The Cerbat Gem